P406 Mucosal healing in children with Crohn's disease on long term maintenance treatment

Introduction. There is little information on the reasons for discontinuing infliximab treatment in patients with Crohn's disease. The aim of this study was to document these reasons to determine if any were preventable which would allow patients to continue the therapy. Aims & Methods. A review of the medical notes was conducted at the Norfolk and Norwich University Hospital on patients with Crohn's disease treated with infliximab between 2002–2008 to determine the reasons for stopping it. Results. A total of 65 patients were identified who had treatment with infliximab, of whom 23 (35.3%) had their therapy stopped. The reasons for discontinuation of infliximab in the 23 patients were: 47.8% side effects, 17.4% refractory disease, 13.0% achieved remission and did not receive long-term maintenance treatment, 4.34% pregnancy, 4.34% death, and unknown 13.0%. Conclusions. The main reasons for the discontinuation of infliximab were side effects rather than a lack of clinical response.

Download Full-text

P102 COMPLEX PERIANAL CROHN'S DISEASE: INFLUENCE OF THE LONG-TERM MAINTENANCE TREATMENT WITH INFLIXIMAB ON THE FISTULAE TRACKS ASSESSED THROUGH MAGNETIC RESONANCE

Journal of Crohn s and Colitis Supplements ◽

10.1016/s1873-9954(08)70113-7 ◽

2008 ◽

Vol 2 (1) ◽

pp. 36

Author(s):

M.I. Calvo ◽

M.I. Vera ◽

J. De la Revilla ◽

F. García ◽

M. Pastrana ◽

...

Keyword(s):

Crohn’S Disease ◽

Magnetic Resonance ◽

Crohn's Disease ◽

Maintenance Treatment ◽

Perianal Crohn’S Disease ◽

Term Maintenance ◽

Perianal Crohn's Disease

Download Full-text

Withdrawal of Long-Term Maintenance Treatment with Azathioprine Tends to Increase Relapse Risk in Patients with Crohn’s Disease

Digestive Diseases and Sciences ◽

10.1007/s10620-014-3419-5 ◽

2014 ◽

Vol 60 (5) ◽

pp. 1414-1423 ◽

Cited By ~ 23

Author(s):

Heimo H. Wenzl ◽

Christian Primas ◽

Gottfried Novacek ◽

Alexander Teml ◽

Anna Öfferlbauer-Ernst ◽

...

Keyword(s):

Crohn’S Disease ◽

Crohn's Disease ◽

Maintenance Treatment ◽

Relapse Risk ◽

Term Maintenance

Download Full-text

W1268 The Course of Infliximab Discontinuation After Long-Term Maintenance Treatment in Crohn's Disease

Gastroenterology ◽

10.1016/s0016-5085(10)63159-9 ◽

2010 ◽

Vol 138 (5) ◽

pp. S-687

Author(s):

Alessandro Armuzzi ◽

Marina Rizzi ◽

Rita Monterubbianesi ◽

Manuela Marzo ◽

Michele Cicala ◽

...

Keyword(s):

Crohn’S Disease ◽

Crohn's Disease ◽

Maintenance Treatment ◽

Term Maintenance

Download Full-text

Management of Crohn’s disease in an immunosuppressed COVID-19-positive patient: safety-driven prioritisation of nutritional therapy as a bridge to restarting immunosuppression

BMJ Case Reports ◽

10.1136/bcr-2020-239404 ◽

2021 ◽

Vol 14 (3) ◽

pp. e239404

Author(s):

Clare Harris ◽

Richard James Harris ◽

Louise Downey ◽

Markus Gwiggner

Keyword(s):

Risk Factors ◽

Inflammatory Bowel Disease ◽

Patient Safety ◽

Crohn’S Disease ◽

Crohn's Disease ◽

Nutritional Therapy ◽

Interleukin 12 ◽

Inflammatory Bowel ◽

Term Maintenance

Active inflammatory bowel disease (IBD), combined immunosuppression and corticosteroid therapy have all been identified as risk factors for a poor outcome in COVID-19 infection. The management of patients with both COVID-19 infection and active IBD is therefore complex. We present the case of a 31-year-old patient with Crohn’s disease, on dual immunosuppression with infliximab and mercaptopurine presenting with inflammatory small bowel obstruction and COVID-19 infection. The case highlights the use of nutritional therapy, which remains underused in the management of adults with IBD, to manage his flare acutely. Following negative SARS-CoV-2 PCR testing and SARS-CoV-2 IgG testing confirming an antibody response, ustekinumab (anti-interleukin 12/23) was prescribed for long-term maintenance.

Download Full-text